Evidence map›Paper›PMID 27134130›Full record

SynthesisInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2016

A systematic review of regional hyperthermia therapy in bladder cancer.

Thomas A Longo, Ajay Gopalakrishna, Matvey Tsivian, Megan Van Noord, Coen R Rasch, Brant A Inman, Elisabeth D Geijsen

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Gold nanorod-assisted theranostic solution for nonvisible residual disease in bladder cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. [Organ-preserving treatment of bladder cancer].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Article
  18. Heated Intravesical Chemotherapy: Biology and Clinical Utility.The Urologic clinics of North America · 2020
    Review
  19. Article
  20. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Thomas A Longoa Division of Urology , Duke University Medical Center , Durham , North Carolina ;
Ajay Gopalakrishnaa Division of Urology , Duke University Medical Center , Durham , North Carolina ;
Matvey Tsiviana Division of Urology , Duke University Medical Center , Durham , North Carolina ;
Megan Van Noordb Research and Education Services, Duke University Medical Center , Durham , North Carolina , USA ;
Coen R Raschc Academic Medical Centre , Amsterdam , the Netherlands.
Brant A Inmana Division of Urology , Duke University Medical Center , Durham , North Carolina ;
Elisabeth D Geijsenc Academic Medical Centre , Amsterdam , the Netherlands.
Duke Medical Center · USAcademic Medical Center · NLDuke University Hospital · US

Funding

Duke CTSA (Composite)KL2TR001115 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$5.1M
Duke CTSA (Composite)TL1TR001116 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$1.2M
NCATS NIH HHS KL2 TR001115NCATS NIH HHS TL1 TR001116
6 · The paper itself

Abstract

contextBladder cancer therapy remains suboptimal as morbidity and mortality remain high amongst those with non-muscle-invasive and muscle-invasive disease. Regional hyperthermia therapy (RHT) is a promising adjunctive therapy being tested in multiple clinical contexts.

objectiveThe aim of this study was to systematically review the literature on the efficacy and toxicity of RHT. EVIDENCE ACQUISITION: This systematic review was registered with the PROSPERO database (Registration number: CRD42015025780) and was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We queried PubMed, EMBASE, and Cochrane libraries. Two reviewers reviewed abstracts independently and a third reviewer arbitrated disagreements. The last search was performed on 28 August 2015. A descriptive analysis was performed and quality assessment was conducted using the Newcastle-Ottawa Quality Assessment Scale for observational studies, and the Cochrane Risk of Bias Assessment Tool for trials. EVIDENCE SYNTHESIS: We identified 859 publications in the initial search, of which 24 met inclusion criteria for full-text review. Of these, we were able to obtain data on the outcomes of interest for 15 publications.

conclusionsThe review underscores the limited nature of the evidence; definitive conclusions are elusive. However, the promising results of RHT in the setting of intravesical chemotherapy, chemotherapy and radiotherapy show a trend towards legitimate efficacy.

Indexed as

Hyperthermia, InducedHumansTreatment OutcomeUrinary Bladder NeoplasmsBladder cancerchemohyperthermiaradiohyperthermiaregional hyperthermia therapyurothelial carcinoma

Identifiers

PMID27134130
PMCPMC5440174
OpenAlexW2345595560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.